Alpha-receptor blocker subtype selectivity t, dose and duration of action are summarized in Table 2. Phenoxybenzamine is not suitable for alpha 1 against alpha-adrenergic NVP-LDE225 LDE225 receptor 2-selective. Prazosin, terazosin, doxazosin and alfuzosin selective for the alpha-1 receptor, but not subtype. Tamsulosin is a relatively h Affinity here T for the alpha-adrenergic receptor 1A and 1B in terms of selectivity not T for the alpha-1A subtype compared 1D receptor. Several big e, randomized, controlled trials Strips placebo supports the safety and efficacy of alpha blocker for the treatment of BPH. Table 3 summarizes the clinical results for some of the most important clinical studies on alpha-blocker. Phenoxybenzamine has been effective in relieving symptoms of BPH, but its use is governed by severe side effects nkt strong eingeschr.
About 30% of patients experienced KX2-391 Src inhibitor adverse effects related to phenoxybenzamine. Orthostatic hypotension is the most important side effect, however, reflex tachycardia, nasal congestion, diarrhea, miosis, sedation, nausea and vomiting are also associated. Interaction between phenoxybenzamine and other antihypertensives and / or vasodilators, may cause additive blood pressure lowering effect. Due to the availability of alpha-1-selective drugs, it is used infrequently for BPH. Prazosin, an alpha-blocker selective, has shown comparable efficacy without serious side-effect profile than phenoxybenzamine. But a first dose phenomenon Ph, The patient experienced sw Surface, are dizziness, palpitations, syncope, and even associated with prazosin use.
The incidence of these side effects can be minimized by dose titration and dose at bedtime. Terazosin has demonstrated safety and efficacy in the treatment of BPH. Bug’s controlled trials against placebo Lee showed a increased Hte peak urine flow, improved Lebensqualit t Y-27632 and scores compared to placebo AUASI The h Ufigsten side effects were dizziness and asthenia with respective rates of 6, or 7% to 19.8% and 3.8% to 12.3%. Sixteen percent of patients on terazosin against 11% for placebo withdrew from the study Hytrin community assessment based on the treatment of side effects. Overall, controlled studies Strips can placebo suggest that terazosin is effective in reducing the symptoms of BPH and improving Lebensqualit t in patients with LUTS. However, some patients can not tolerate, and terazosin may k Benefit from another drug.
Doxazosin has demonstrated safety and efficacy in the treatment of BPH. It has also been used to lower blood pressure in hypertensive, normotensive patients presented with no implementation. However, it was antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial a big e, randomized, double-blind, controlled Active EAA designed to detect differences in the randomized kardiovaskul Ren events in patients with hypertension, chlorthalidone, doxazosin, amlodipine or lisinopril. The doxazosin arm of this study was prematurely because of significantly h Higher proportion of the combination of several Ph Nomena cardiovascular disease, heart failure, in particular closed. Prior to this study, alpha-blockers hour Frequently a first choice drug for the treatment of high blood pressure, particularly in patients with concomitant diseases, BPH, however, demonstrated the results of the ALLHAT study that doxazosin group had an increase